What it's for (Indications)
- Thiocolchicoside is indicated as an adjuvant treatment for the symptomatic relief of painful muscle contractures in adults and adolescents aged 16 years and older.
- These contractures are often associated with acute spinal pathology, such as lumbago, torticollis, or other musculoskeletal conditions involving localized muscle spasm and pain.
- It is intended for short-term use to alleviate muscle rigidity and associated discomfort, thereby facilitating physical therapy and improving patient mobility.
- This medication is not a primary treatment for underlying conditions but rather a supportive therapy to manage associated muscle spasms.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For oral administration, the recommended maximum dose of thiocolchicoside is 8 mg per day, administered either as 4 mg twice daily or 8 mg once daily. The duration of treatment must be strictly limited to a maximum of 7 consecutive days due to significant genotoxicity concerns associated with a major metabolite of the drug. For intramuscular (IM) administration, if available and deemed appropriate by a healthcare professional, the typical recommended dose is 4 mg every 12 hours, with a maximum duration of 5 days. Dosage adjustments may be necessary in patients with renal or hepatic impairment, and in some cases, the drug may be contraindicated. Treatment should always be initiated and closely monitored under strict medical supervision, and patients must not exceed the recommended dose or duration. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects of thiocolchicoside include various gastrointestinal disturbances such as diarrhea, nausea, vomiting, and epigastralgia.
- Central nervous system effects, particularly somnolence (drowsiness), are also frequently observed, which can significantly impair the ability to drive or operate hazardous machinery.
- Less common but potentially severe adverse reactions include a range of allergic manifestations, which can present as pruritus, urticaria, angioedema, and in rare instances, life-threatening anaphylactic shock.
- Neurological events like vasovagal syncope, especially following intramuscular administration, and infrequent occurrences of convulsive seizures have been reported.
- Patients with a history of epilepsy or conditions predisposing to seizures should exercise extreme caution.
- Any unusual, severe, or persistent symptoms should be promptly reported to a healthcare provider.
Serious Warnings
- Black Box Warning: **Serious Warnings: Genotoxicity and Potential Reproductive Risks** Thiocolchicoside carries significant warnings regarding its potential for genotoxicity, which is directly linked to its primary metabolite, SL59.0955 (M2). *In vitro* studies have conclusively demonstrated that this metabolite is a potent inducer of aneuploidy (abnormal number of chromosomes), primarily through its interaction with the tubulin polymerization process, resembling the known antimitotic effects of colchicine. Aneuploidy is a serious concern as it is a known risk factor for impaired human fertility (both male and female), embryonic/fetal toxicity, teratogenicity (birth defects), and has been associated with an increased risk of cancer. Due to these serious genotoxic and reproductive safety concerns, the following restrictions and warnings are imperative: 1. **Pregnancy and Lactation:** Thiocolchicoside is strictly contraindicated during pregnancy and in women who are breastfeeding due to the high risk of genotoxicity and potential harm to the developing fetus or infant. 2. **Women of Childbearing Potential:** Women of childbearing potential must use highly effective contraception throughout treatment. The decision to prescribe thiocolchicoside in this population should only be made after a thorough evaluation of the individual risks and benefits, and only when non-thiocolchicoside therapies are unsuitable or ineffective. 3. **Dosage and Duration Restrictions:** To minimize exposure to the genotoxic metabolite, treatment with thiocolchicoside must be strictly limited to a maximum daily oral dose of 8 mg and for a maximum duration of 7 consecutive days. Exceeding these recommendations significantly increases the theoretical risk of chromosomal damage and adverse outcomes. 4. **Male Fertility:** While direct human data are limited, the aneuploidy-inducing potential raises theoretical concerns regarding potential adverse effects on male fertility. Healthcare professionals must ensure patients are fully informed of these severe risks before commencing treatment and adhere rigorously to all prescribing guidelines to mitigate potential harm.
- Patients should be thoroughly informed about the critical safety concerns associated with thiocolchicoside.
- Due to the genotoxic potential of its major metabolite, SL59.
- 0955 (M2), there is a significant theoretical risk of aneuploidy (abnormal number of chromosomes) induction.
- This potential for chromosomal damage necessitates strict adherence to the recommended dosage and treatment duration (maximum 7 days, 8 mg/day) to minimize human exposure.
- The drug is strictly contraindicated in children under 16 years of age.
- Caution is advised in patients with a history of epilepsy or those predisposed to convulsions, as rare instances of seizures have been reported.
- Furthermore, patients should be warned about the potential for somnolence, which can significantly impair the ability to drive or operate hazardous machinery.
- Hypersensitivity reactions, including severe anaphylaxis, although rare, require immediate medical attention.
- It is crucial to inform healthcare providers about any pre-existing conditions or concurrent medications.
How it Works (Mechanism of Action)
Thiocolchicoside is a semi-synthetic derivative of colchicoside, a naturally occurring glucoside extracted from plants. Its muscle relaxant properties are primarily mediated through its central action within the nervous system. The drug is believed to act as a potent antagonist of GABA-A receptors and an agonist at glycine receptors, both of which are key inhibitory neurotransmitter systems in the spinal cord and supraspinal centers. By modulating these pathways, thiocolchicoside effectively reduces muscle tone and spasticity without inducing a curarizing effect, thereby avoiding muscular paralysis. A critical aspect of its pharmacology relates to its primary metabolite, SL59.0955 (M2), which has been demonstrated in *in vitro* studies to induce aneuploidy through its interaction with tubulin polymerization, akin to the antimitotic effects of colchicine. This genotoxic potential of the metabolite is a key factor guiding its restricted clinical use, dosage, and duration.